What are the public health effects of direct-to-consumer drug advertising?

Elizabeth A. Almasi, Randall S. Stafford, Richard L Kravitz, Peter R. Mansfield

Research output: Contribution to journalArticlepeer-review

67 Scopus citations


Background to the debate: Only two industrialized countries, the United States and New Zealand, allow direct-to-consumer advertising (DTCA) of prescription medicines, although New Zealand is planning a ban [1]. The challenge for these governments is ensuring that DTCA is more beneficial than harmful. Proponents of DTCA argue that it helps to inform the public about available treatments and stimulates appropriate use of drugs for high-priority illnesses (such as statin use in people with ischemic heart disease). Critics argue that the information in the adverts is often biased and misleading, and that DTCA raises prescribing costs without net evidence of health benefits.

Original languageEnglish (US)
Pages (from-to)284-288
Number of pages5
JournalPLoS Medicine
Issue number3
StatePublished - Mar 2006

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'What are the public health effects of direct-to-consumer drug advertising?'. Together they form a unique fingerprint.

Cite this